Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm focused on autoimmune and inflammatory diseases, will attend the Jefferies London Healthcare Conference from November 15-17, 2022. Rachelle Jacques, President and CEO, along with the management team, will hold one-on-one meetings with registered investors. The company is advancing its lead product, nomacopan, which targets severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and is also exploring long-acting formulations for geographic atrophy.

NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Jefferies London Healthcare Conference scheduled to take place November 15-17, 2022. President and CEO Rachelle Jacques and the Akari management team will attend 1:1 meetings with investors who are registered for the conference.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward- looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com 

Media Contact:
Eliza Schleifstein
Schleifstein PR
(917) 763-8106
eliza@schleifsteinpr.com 

FAQ

What is the purpose of Akari Therapeutics' attendance at the Jefferies London Healthcare Conference?

Akari Therapeutics will participate in one-on-one meetings with investors to discuss its developments and strategies.

When is the Jefferies London Healthcare Conference taking place?

The conference is scheduled for November 15-17, 2022.

What is Akari Therapeutics' lead product?

The lead product is nomacopan, which is being developed for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.

What stage is nomacopan currently in?

Nomacopan is in a Phase 3 clinical trial program.

What other research is Akari Therapeutics conducting?

They are conducting pre-clinical research on long-acting PAS-nomacopan for geographic atrophy.